$6.15
1.82% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US00773U1088
Symbol
ADVM
Sector
Industry

Adverum Biotechnologies Inc Stock price

$6.15
-1.83 22.93% 1M
-1.45 19.08% 6M
-1.38 18.31% YTD
-2.35 27.64% 1Y
-14.15 69.70% 3Y
-98.05 94.10% 5Y
-380.75 98.41% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.11 1.82%
ISIN
US00773U1088
Symbol
ADVM
Sector
Industry

Key metrics

Market capitalization $127.94m
Enterprise Value $47.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 47.96
P/S ratio (TTM) P/S ratio 127.94
P/B ratio (TTM) P/B ratio 0.89
Revenue growth (TTM) Revenue growth -72.22%
Revenue (TTM) Revenue $1.00m
EBIT (operating result TTM) EBIT $-113.90m
Free Cash Flow (TTM) Free Cash Flow $-86.14m
Cash position $153.24m
EPS (TTM) EPS $-6.03
P/E forward negative
P/S forward 127.94
EV/Sales forward 47.96
Short interest 7.77%
Show more

Is Adverum Biotechnologies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Adverum Biotechnologies Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy
88%
Hold
13%

Financial data from Adverum Biotechnologies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1 1
72% 72%
100%
- Direct Costs 3.85 3.85
71% 71%
385%
-2.85 -2.85
71% 71%
-285%
- Selling and Administrative Expenses 39 39
62% 62%
3,917%
- Research and Development Expense 68 68
20% 20%
6,802%
-110 -110
7% 7%
-11,005%
- Depreciation and Amortization 3.85 3.85
71% 71%
385%
EBIT (Operating Income) EBIT -114 -114
14% 14%
-11,390%
Net Profit -94 -94
25% 25%
-9,411%

In millions USD.

Don't miss a Thing! We will send you all news about Adverum Biotechnologies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adverum Biotechnologies Inc Stock News

Neutral
GlobeNewsWire
6 days ago
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee...
Positive
Seeking Alpha
8 days ago
Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS study, using Ixo-vec in combination with prophylactic regimens for the treatment of patients with wet age-related macular degeneration, expected to begin 1st half of 2025. The global age-related m...
Neutral
GlobeNewsWire
11 days ago
– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a.m. EST
More Adverum Biotechnologies Inc News

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office United States
CEO Laurent Fischer
Employees 121
Founded 2006
Website www.adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today